Financing channel feed – Endpoints News

Financing channel feed

London's biopharma-focused GHO Capital Partners claims close of largest-ever European fund

6 years ago

Here's a $25M seed fund aimed at backing some brash new drug ideas out of the Broad

6 years ago

Investors could emerge from Neil Woodford debacle with £1B loss, internal analysis reveals

6 years ago

Flagship woos Novartis top dealmaker Prakash Raman in move to get the BD ball rolling early

6 years ago

Tot Biopharm completes HKEX listing, raising $63M in modest debut

6 years ago

Monopar delays IPO again despite slashing offering while a micro-cap biotech clinches $9M

6 years ago

New cell therapy player launches with $57M from marquee investors to go after 'definitive' tumor targets

6 years ago

Teva spinout delays NASH IPO while Galera prices below range

6 years ago

George Church startup eGenesis rakes $100M to ramp up CRISPR pig organ transplants

6 years ago

New Amplitude fund looks to bet over $100 million on incipient Canadian biotech market

6 years ago

AstraZeneca sketches plans for a $1B venture fund — and it's going to China

6 years ago

Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies

6 years ago

SinoMab BioScience, Alphamab Oncology make their way to the Hong Kong Stock Exchange

6 years ago

Buoyed by blockbuster Vertex payments, the CF Foundation seeds new advances with $500M fund

6 years ago

In a bid to get to Chinese patients faster, Shanghai's I-Mab plans $100M Nasdaq IPO

6 years ago

Why Scott Gottlieb, venture capitalist, sees opportunity in antibiotics

6 years ago

Atlas, Novo-backed biotech reels in ex-Nimbus CEO Don Nicholson as exec chairman, hooks $50M to conquer anemia

6 years ago

David Hung is back, launching a new oncology startup with $275M and big ambitions to make news in cancer drug development

6 years ago

Google’s venture arm recruits a Harvard/Tesaro vet to help plant the seeds for a second oncology R&D revolution

6 years ago

Ascentage soars during its first day on the Hong Kong exchange, following $53M debut

6 years ago

China's Fountain Medical scores $62M as demand for CRO services surges

6 years ago

A tale of two IPOs (plus one): Cabaletta prices well below range for $75M while Phathom bags $182M

6 years ago

RAPT Therapeutics returns to Wall Street to revive IPO bid

6 years ago

Frazier Healthcare Partners' dermatology upstart attracts a marquee syndicate, $94M+ for 'in-between' topical drug

6 years ago

First page Previous page 106 107 108109110 111 112 Next page Last page